FTI-276 - patents, research & applications

147Patents

31Research papers

19Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Pfizer Inc	26
2	Cincinnati Children's Hospital Medical Center	19
3	State University System of Florida	9
4	University of Pittsburgh	9
5	Yale University	8

6	Massachusetts Institute of Technology	7
7	Alcon Inc	5
8	Eiger Biopharmaceuticals Inc	4
9	Cellectis SA	3
10	Harvard University	3

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61P`	Therapeutic activity (drug indications)	125
2	`A61K`	Medicinal preparations	118
3	`C07K`	Peptides	49
4	`C07D`	Heterocyclic compounds	36
5	`Y02A`	Climate change adaptation	19

6	`G01N`	Investigating / analysing materials	14
7	`C07C`	Acyclic and carbocyclic compounds	9
8	`C12N`	Microorganisms, enzymes	7
9	`C12Q`	Measuring/testing involving enzymes	7
10	`A23L`	Foods and beverages (general)	5

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

Title	Year	Assignee	Cited by
ShK toxin compositions and methods of use	2000	Bachem Holding AG	91
TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS	2011	Eiger Biopharmaceuticals Inc	35
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase	2001	Pfizer Inc	57
AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION	2011	Eiger Biopharmaceuticals Inc	34
METHOD FOR TREATING CANCER HARBORING A p53 MUTATION	2012	Columbia University	28

How research activity has moved

Papers published per year for this compound, over the last decade of indexed records.

Year	Papers
2016	1
2017	2

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Andrew D. Hamilton	Yale University	7
2	Junko Ohkanda	Yale University	4
3	Joëlle Dubois	Institut de Chimie des Substances Naturelles	4
4	Saı̈d M. Sebti	Moffitt Cancer Center	4
5	Zhongqiu Zhang	University of Toledo	3

6	Ronald A. Lubet	National Cancer Institute	3
7	Saı̈d Sebti	University of South Florida	3
8	Ming You	University of Toledo	3
9	Jerry D. Cohen	Abbott (United Kingdom)	3
10	Jeffrey W. Lockman	Yale University	3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
Targeting RAS signalling pathways in cancer therapy	2003	3264	Protein Kinase Regulation and GTPase Signaling
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes	1995	363	Protein Kinase Regulation and GTPase Signaling
Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS1	2000	74	Protein Kinase Regulation and GTPase Signaling
Ras‐MEK‐ERK signaling cascade regulates androgen receptor element‐inducible gene transcription and DNA synthesis in prostate cancer cells	2007	54	Prostate Cancer Treatment and Research
Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone	2000	47	Protein Kinase Regulation and GTPase Signaling

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of FTI-276?

FTI-276 has the molecular formula C21H27N3O3S2 with a molecular weight of 433.585. Its canonical IUPAC name is (2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid, and it is also known by the synonym (2S)-2-((4-(((2R)-2-amino-3-sulfanylpropyl)amino)-2-phenylbenzoyl)amino)-4-methylsulfanylbutanoic acid.

Which organizations hold the most patents related to FTI-276?

Pfizer Inc leads with 26 patents, followed by Cincinnati Children's Hospital Medical Center with 19 patents and State University System of Florida with 9 patents. University of Pittsburgh and Yale University each hold 9 and 8 patents respectively.

What research topics are associated with FTI-276 in the scientific literature?

The published literature on FTI-276 focuses on Protein Kinase Regulation and GTPase Signaling as the primary research topic. For example, one paper examined how FTI-276 blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes, while another investigated the effect of FTI-276 on established lung adenomas in animal models.

How has patent activity for FTI-276 evolved in recent years?

Patent activity has increased significantly, with 13 patents in 2024 and 5 in 2025, compared to only 1 patent in 2020. The period from 2021 to 2024 showed sustained growth, with 7 patents in 2021, 10 in 2022, and 5 in 2023. In the last three years, there have been 19 patents filed.

Who are the most prolific authors publishing on FTI-276?

Andrew D. Hamilton from Yale University is the most prolific author with 7 papers on FTI-276. Junko Ohkanda, also from Yale University, has published 4 papers. Other notable contributors include Joëlle Dubois from Institut de Chimie des Substances Naturelles and Saïd M. Sebti from Moffitt Cancer Center, each with 4 papers.